MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

Is Ionis Pharmaceuticals Poised for a Breakthrough with Tryngolza

3 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Is Rhythm Pharmaceuticals Poised for a Breakthrough in Hypothalamic Obesity

3 months ago

Is EcoSolutions Waste Poised for a Biofuel Breakthrough

3 months ago

Is Protagenic Therapeutics (PTIX) Poised for a Breakthrough in Neuropsychiatric Treatment

1 months ago

Is TeraDrill (TDRL) Poised for a Breakthrough in Mining Automation

1 months ago

QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval

QURE surged after the FDA said AMT-130 phase I/II data could support an accelerated approval filing for Huntington's disease.

QURE

Stock News•1 week ago

Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?

Alnylam's Amvuttra drove rapid sales growth, reshaping revenue mix. Fresh ATTR-CM approvals could unlock a larger market, sustaining momentum if adoption accelerates.

ALNY

Stock News•4 weeks ago

Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts

Ionis Pharmaceuticals is entering a broader commercial and late-stage development phase, highlighted by an upcoming regulatory decision for TRYNGOLZA and five Phase 3 clinical readouts. The company ai...

IONS

Stock News•1 months ago

This Drug Stock Nears A Buy Point, With Profit Set To Explode

A biopharma stock is currently testing a key moving average within a technical base. The company utilizes proprietary, patented technology for its drug administration, which may influence future marke...

LQDA